Explore

GLP-1 Weight Loss Drugs Show Mixed Results in Alzheimer's Trials, Promising for Brain Health in Metabolic Conditions

GLP-1 Weight Loss Drugs Show Mixed Results in Alzheimer's Trials, Promising for Brain Health in Metabolic Conditions

New research published in Science indicates that GLP-1 weight loss drugs, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), are being investigated for their potential effects on brain health. While observational studies have linked these drugs to a reduced risk of cognitive impairment and dementia, and animal studies suggest they can influence learning and memory, clinical trials present a more nuanced picture. Specifically, Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials found that semaglutide did not slow the clinical progression of Alzheimer's disease in individuals already experiencing early symptoms, despite showing positive changes in some disease-related biomarkers. Researchers, including Stina Börchers and Christoffer Clemmensen, suggest that the effect on Alzheimer's progression might be too small, with semaglutide lowering nerve-cell damage markers by about 10 percent compared to 30 percent for other drugs known to slow Alzheimer's. The review highlights that these drugs ...

UCLA Health Study Links Common Pesticide Chlorpyrifos to Increased Parkinson's Risk

UCLA Health Study Links Common Pesticide Chlorpyrifos to Increased Parkinson's Risk

A new study from UCLA Health indicates that long-term exposure to the widely used pesticide chlorpyrifos may significantly increase the risk of Parkinson's disease. The research suggests that individuals with prolonged residential exposure to chlorpyrifos face more than 2.5 times the risk of developing Parkinson's compared to those not similarly exposed. This finding is based on data from the Parkinson’s Environment and Genes study, which analyzed information from 829 people with Parkinson's and 824 without the condition, correlating their residential and workplace histories with detailed pesticide application records in California. Laboratory experiments involving mice exposed to aerosolized chlorpyrifos for 11 weeks showed movement difficulties, loss of dopamine-producing neurons, brain inflammation, and abnormal alpha-synuclein accumulations, mirroring key features of human Parkinson's. Further studies using zebrafish revealed that chlorpyrifos disrupts autophagy, a cellular cleanup process, leading to ...

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

New Research Reveals Distinct Tau Pathology in Early-Onset Alzheimer's, Suggesting Tailored Treatment Approaches

A new study has revealed that early-onset Alzheimer's disease, which affects individuals under 65, exhibits a distinct and more aggressive tau pathology compared to late-onset Alzheimer's. Researchers compared 390 early-onset patients (average age 59) with 211 late-onset patients (average age 78), all with mild cognitive impairment or mild dementia and confirmed amyloid positivity. The study found that early-onset patients had higher initial levels of tau, spread across more brain regions, and accumulated tau twice as fast. This aggressive tau accumulation was more strongly linked to memory loss progression in younger patients. The findings suggest that early-onset Alzheimer's is not merely an earlier manifestation of the late-onset form but a distinct disease process, often presenting with non-memory-dominant symptoms like difficulties with language, vision, or executive functions.

Mass General Brigham Researchers Highlight Tailored iPSC-Based Therapies for Neurodegenerative Diseases

Mass General Brigham Researchers Highlight Tailored iPSC-Based Therapies for Neurodegenerative Diseases

Researchers at Mass General Brigham have emphasized that induced pluripotent stem cell (iPSC)-based therapies for neurodegenerative diseases must be tailored to the specific biology of each condition. Their review, spanning 20 years of iPSC research, indicates that a single therapeutic strategy is unlikely to be effective for all neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). The research highlights that PD is the most advanced model for neuronal replacement due to its well-defined cell loss, while HD, AD, and ALS present more complex challenges requiring combinations of cell replacement, cellular support, immune modulation, or engineered therapeutic delivery. The study also focuses on the critical period after cell delivery, referred to as a 'biological black box,' where factors like injury, immune responses, tissue remodeling, and integration significantly influence the fate of transplanted cells...

Harvard Medical School Researchers Link Low Lithium Levels to Alzheimer's, Show Promise in Mice

Harvard Medical School Researchers Link Low Lithium Levels to Alzheimer's, Show Promise in Mice

Researchers at Harvard Medical School, led by neuroscientist Bruce Yankner and first author Liviu Aron, have published findings in Nature indicating a potential link between lower lithium levels in the brain and Alzheimer's disease. Their study, conducted in collaboration with Rush University in Chicago, analyzed donated human brain tissue and found that lithium was the only one of 27 measured metals significantly lower in a brain region vulnerable to Alzheimer's in individuals with mild cognitive impairment and Alzheimer's disease. The team also observed that amyloid plaques, a hallmark of Alzheimer's, appeared to trap lithium, thereby reducing its availability to surrounding brain tissue. Subsequent experiments in mice demonstrated that reducing lithium levels led to more Alzheimer's-related brain changes and memory difficulties. Conversely, administering low doses of lithium orotate to these mice reduced some of these changes and improved their memory performance. This research suggests that a shortage ...

Milken Institute Highlights Critical Gaps in Menopause and Brain Health Research

Milken Institute Highlights Critical Gaps in Menopause and Brain Health Research

The Milken Institute Women’s Health Network has released a brief titled 'Menopause and Brain Health: What Women Need to Know,' which underscores significant research gaps concerning menopause, particularly its impact on brain health. The report emphasizes that while menopause is primarily seen as a reproductive transition, it is also a crucial brain health transition. Hormonal changes during this period interact with sleep, mood, hot flashes, stress, and overall health, influencing how women think, feel, and function. The brief notes that cognitive symptoms like memory difficulties, concentration issues, and 'brain fog' are real and can affect daily life, work, and confidence, though they are generally subtle and distinct from more serious cognitive conditions. The Milken Institute aims to improve awareness, care, and support for women experiencing these changes.

Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Approach

Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Approach

Roche announced it will present new data from its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in Boston, MA, from November 16–19, 2026. The company plans to showcase 16 accepted abstracts, including two scientific symposia and two oral presentations. A key highlight is the initiation of a new Phase II clinical trial, TARBELA-AD, which will evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer’s disease. This trial signifies Roche's strategy to target neuroinflammation, alongside its ongoing efforts to address amyloid aggregation with candidates like trontinemab. Dr. Levi Garraway, Roche’s Chief Medical Officer, emphasized the need for multifaceted strategies to combat the complexity of Alzheimer's. Additionally, Roche's diagnostics division will present data on its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests, aimed at enabling earlier and more accurate diagnosis.

Exercise and Fasting Offer Distinct Yet Complementary Pathways for Brain Health, Study Suggests

Exercise and Fasting Offer Distinct Yet Complementary Pathways for Brain Health, Study Suggests

Exercise and Fasting Offer Distinct Yet Complementary Pathways for Brain Health, Study Suggests

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche has announced the initiation of a new Phase II clinical trial, TARBELA-AD, to evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer's disease. This study is part of Roche's broader strategy to address Alzheimer's by targeting various biological mechanisms, specifically focusing on neuroinflammation as a key driver of pathology in addition to amyloid aggregation. The announcement was made in anticipation of the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress in Boston, scheduled from November 16-19, 2026. According to Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, this trial aims to test additional therapeutic hypotheses to potentially halt or prevent disease progression, complementing their ongoing trontinemab programs. Roche's diagnostics division is also expanding access to earlier and more accurate Alzheimer's diagnosis through its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests.

New Dementia Study Links Estrogen Exposure to Better Brain Health in Women

New Dementia Study Links Estrogen Exposure to Better Brain Health in Women

A new study published in Neurology has suggested a link between estrogen exposure and healthier brain vessels, potentially impacting brain health in women. The research, involving 352 women with a mean age of 70, found that women with a longer reproductive lifespan—meaning a longer period of natural estrogen exposure from their first period to menopause—tended to show fewer signs of damage to the brain's small blood vessels. Additionally, women who had used estrogen-based oral contraceptives or menopausal hormone therapy (MHT) were more likely to exhibit signs of improved brain health, including stronger connections between different brain regions and, for MHT users, fewer signs of small blood vessel damage. Alzheimer's Research UK acknowledged these findings as 'interesting' but emphasized that, as an observational study, it cannot prove cause and effect, and more research is needed.

University of Texas at Dallas Research Challenges Cognitive Decline, Shows Brain Health Improvement Across Adulthood

University of Texas at Dallas Research Challenges Cognitive Decline, Shows Brain Health Improvement Across Adulthood

Lori Cook, Director of Clinical Research at the Center for BrainHealth at the University of Texas at Dallas, has presented new research challenging the long-held belief that cognitive decline is an inevitable part of aging. Her team followed nearly 4,000 adults, aged 19 to 94, over a three-year period. The study found that brain health can improve across adulthood, rather than merely being protected from decline. Participants engaged in online interventions that included brain strategy training, lifestyle tips, personalized coaching, and ongoing performance tracking using the BrainHealth Index™. This index measures clarity of thinking, emotional balance, and a sense of connectedness. The research indicated that both young and older adults showed improvements, with those starting with lower brain health often making the most significant gains. Crucially, the study highlighted that these improvements were not passive, with the greatest gains observed in individuals who consistently adopted brain-healthy habi...

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

The field of brain health research is evolving beyond simply identifying beneficial nutrients to understanding how these nutrients are absorbed, transported, and utilized by the brain. Scientists are now investigating the complex processes of nutrient delivery, such as how docosahexaenoic acid (DHA), a crucial omega-3 fatty acid, crosses the blood-brain barrier. A landmark study published in Nature identified a transporter called MFSD2A, which facilitates DHA movement into the brain when attached to lysophosphatidylcholine (LPC). This discovery highlights that the molecular form of a nutrient can significantly influence its brain accessibility. Additionally, there is a growing interest in personalized nutrition, recognizing that individual differences in age, health status, and metabolism may require tailored dietary recommendations rather than generalized approaches. This shift aims to provide a more detailed understanding of the relationship between nutrition and brain function.